Contact: Beth Casteel, email@example.com, 240-328-4549CHICAGO (March 26, 2012) — A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism – a blockage of lung blood vessels usually caused by a clot – and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology’s 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
Pulmonary embolism (PE) and deep vein thrombosis (DVT), a blot clot generally occurring in the legs, constitute the two categories of a condition called venous thromboembolism (VTE). VTE is the third most common cardiovascular disease, and PE is the third most common cause of hospital-related death. EINSTEIN-PE is one of a series of large international phase III clinical trials of the anti-coagulant rivaroxaban to treat VTE or prevent a recurrence in patients with acute PE or DVT. The Food and Drug Administration has approved rivaroxaban as the only oral anti-coagulant for prevention of VTE in patients who have knee or hip replacement, procedures that carry clotting risks.
The trial compared rivaroxaban with standard therapy – injection of the anti-coagulant enoxaparin, followed by a vitamin K antagonist (VKA; either warfarin or acenocoumarol) chosen by each participating site – to demonstrate that the oral drug as a single agent is equivalent to the complicated two-drug standard therapy. In the standard regimen, enoxaparin must be given as an injection, and the VKA must be monitored with blood tests to make sure the dose is adequate and safe, because common drugs such as antibiotics, alcohol and some foods interact with VKAs. The monitoring measure is INR, an expression of the time it takes blood to clot: the higher the INR number, the higher the risk of bleeding.
“If you give standard treatment in the right way, it’s a perfectly effective drug with almost 90 percent reduction in recurrent thrombosis, but it has to be well controlled,” said Harry R. Buller, MD, PhD, professor of vascular medicine at the Academic Medical Center, Amsterdam, The Netherlands, who chairs the program for the three EINSTEIN studies. “The reason people look for alternatives is that it’s a nightmare to give. Rivaroxaban makes things easier for everybody – patients and physicians. Our major aim was to show that it’s at least as good as standard care.”
The study, conducted at 263 sites in 38 countries, randomly assigned 2,419 patients to the rivaroxaban arm and 2,414 to standard treatment. All enrolled patients had a primary diagnosis of PE, and 25 percent in both groups also had DVT. Patients were treated for three, six or 12 months (average, seven) as deemed appropriate by each clinician before randomization. The rivaroxaban group received 15 mg twice a day for three weeks followed by 20 mg once a day. In the standard-therapy arm, the regimen was enoxaparin at 1.0 mg per kg of body weight twice daily, continued at least five days and stopped when the INR was 2.0 or more for two consecutive days, plus a VKA started within 48 hours after randomization with dose adjustment to maintain an INR of 2.0 to 3.0.
Rivaroxaban’s efficacy was highly significant for non-inferiority with 2.1 percent recurrences (50 events) vs. 1.8 percent (44 events) in the standard-therapy arm. On safety measures of bleeding, rivaroxaban did much better: principal safety measure of major or clinically relevant bleeding, 10.3 percent vs. 11.4 percent for standard treatment; for major bleeding alone, 1.1 percent vs. 2.2 percent for standard therapy. Rates for primary endpoints were similar in both study arms regardless of patient characteristics.
“Physicians want to know about major bleeding, the most important safety outcome, and rivaroxaban was highly significantly superior. This was our most astonishing finding,” Dr. Buller said. “Rivaroxaban is just as good as standard treatment for PE – these data are pretty convincing – and this is an oral-only approach, which makes it very simple. The subcutaneous injections can be hazardous as well.”
Researchers also will be doing a subgroup analysis of the 8,200 patients in the EINSTEIN-PE and EINSTEIN-DVT trials to see if they can identify a risk profile for patients who are likely to have bleeding problems on standard treatment or the new drug.
The trial was sponsored by Bayer HealthCare and Janssen Pharmaceuticals. Dr. Buller is reimbursed for patients who participate in the study, travel costs and administrative time, and those funds go to the hospital.
This study will be simultaneously published in the New England Journal of Medicine online at the time of presentation and will appear in the April 2012 print edition.
Dr. Buller will be available to the media on Monday, March 26, at 9:45 a.m. CDT in Media Room #1, McCormick Place North Level 1, Hall C1.
Dr. Buller will present the study “Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism: the EINSTEIN PE Study” on Monday, March 26, at 8 a.m. CDT during the Joint ACC/NEJM Late-Breaking Clinical Trials in the Main Tent of McCormick Place North.
About the American College of Cardiology
The American College of Cardiology (www.cardiosource.org) is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College transforms cardiovascular care and improves heart health as it supports and advocates for quality improvement, patient-centered care, payment innovation and professionalism. The ACC bestows credentials upon cardiovascular specialists who meet its stringent qualifications and leads the formulation of health policy, standards and guidelines. It provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality.
The ACC’s Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention.